Please login to the form below

Not currently logged in
Email:
Password:

nivolumab

This page shows the latest nivolumab news and features for those working in and with pharma, biotech and healthcare.

AZ drug matched to cancer mutation passes phase 2 test

AZ drug matched to cancer mutation passes phase 2 test

The first approvals for type-agnostic therapies have already been granted, with Merck/MSD’s Keytruda (pembrolizumab( and Bristol-Myers Squibb’s Opdivo (nivolumab) – both PD-1 checkpoint inhibitors – greenlighted for

Latest news

More from news
Approximately 63 fully matching, plus 221 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    It’s not all been plain sailing, with BMS’Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors –

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche

  • Managed Access Programmes: a powerful source of real-world insight Managed Access Programmes: a powerful source of real-world insight

    Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D; Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population.

  • Managed Access Programmes: a powerful source of real-world insight Managed Access Programmes: a powerful source of real-world insight

    Quadrini S, Antonelli P, Manzo A, Prediletto I, Giannarelli D, Galetta D; Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population.

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics